The path ahead for the FDA
In a Coalition for Healthcare Communication webinar, former FDA exec Nancy Bradish Myers reflected on the agency’s tumultuous 2020 and charted a path forward for 2021.
Regulatory
Health Policy 2021: COVID-19 pandemic, drug pricing, ACA reform and data privacy
Ending the pandemic is clearly the top public-health priority for the incoming Biden administration. Will action on drug pricing, ACA reform and data privacy follow?
“It’s always interesting when there’s a new administration and a new political configuration”
Washington healthcare policy insider Terry Haines offers his thoughts on COVID relief, the future of the Affordable Care Act and more.
Numerous groups are attempting to diversify COVID vaccine research
With communities of color historically underrepresented in clinical trials, numerous groups are working to diversify COVID-19 vaccine research.
FDA cracks down on e-cigarette makers that didn’t submit marketing applications
The agency sent warning letters to vape companies selling e-cigarettes without premarket authorization.
COVID-19 kicks drug pricing down the road
The attention to the upcoming presidential election also dims the likelihood of legislation efforts until 2021.
Pharma industry, Trump publicly negotiate drug pricing rules
President Trump is putting pressure on the pharma industry ahead of the presidential election.
House committee to investigate how USPS slowdown affects prescriptions by mail
The House Energy and Commerce subcommittee on health began an investigation this week.
Telehealth executive order aims to extend temporary changes
President Trump’s executive order calls for regulation to make some of the changes permanent.
Pandemic or no, pharma needs to push drug pricing dialogue
Although the world is still months away from a COVID-19 vaccine, it’s imperative that pharma companies have the conversation right now about the cost of innoculation.
Want to read more?
Please login or register first to view this content.
